Blood coagulation factor replacement product for use in the treatment or prophylaxis of bleedings
AssigneeCSL Behring GmbH
InventorsEva Herzog, Gerald Hochleitner, Oliver Grottke
Life of this patent
Estimating the term…
Abstract
The invention pertains to a blood coagulation factor replacement product for use in the treatment or prophylaxis of bleedings of patients having an acquired coagulation factor deficiency or for use in the treatment or prophylaxis of bleedings of patients having a congenital deficiency of a coagulation factor. Said product comprises at least isolated prothrombin (Factor II) and isolated Antithrombin III (ATIII), whereby the molar ratio between ATIII to Factor II is at least 1:30. By administration of said product the patient's risk for a thromboembolic complication is reduced.
Claims16
A method for treatment or prophylaxis of bleeding in a patient having (i) an acquired coagulation factor deficiency or (ii) a congenital deficiency of a coagulation factor, comprising administering to the patient an effective amount of at least (a) an isolated prothrombin (Factor II), and (b) an isolated Antithrombin III (ATIII), wherein the molar ratio of the ATIII to the Factor II is at least 1:30, and wherein upon administration of (a) and (b), the patient's risk for a thromboembolic complication is reduced.
A method for treatment or prophylaxis of bleeding in a patient having (i) an acquired coagulation factor deficiency or (ii) a congenital deficiency of a coagulation factor, comprising administering to the patient an effective amount of (a) a prothrombin complex concentrate (PCC), and (b) an Antithrombin III (ATIII), wherein the PCC comprises at least prothrombin (Factor II), Factor IX, and Factor X, provided that the molar ratio of the ATIII to the Factor II is at least 1:30, and wherein upon administration of (a) and (b) the patient's risk for a thromboembolic complication is reduced.
Dependencies are inferred from the claim text.